文献速递临床试验与 GCP

阿托伐他汀联合地塞米松治疗慢性硬膜下血肿(ATOCH II):一项随机对照试验的研究方案

Atorvastatin combined with dexamethasone in chronic subdural haematoma (ATOCH II): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-12-11

ATOCH-II 是一项多中心、随机、安慰剂对照、双盲试验,计划纳入 240 例有保守治疗指征的成人慢性硬膜下血肿患者,随机接受阿托伐他汀 20 mg 联合低剂量地塞米松(或匹配安慰剂)每日治疗 28 天,随访 152 天。主要结局为 28 天时血肿体积较基线任何下降且无手术生存的复合良好结局。

要点

  • ATOCH-II 为多中心、随机、安慰剂对照、双盲试验,计划纳入 240 例成人慢性硬膜下血肿患者。
  • 干预为阿托伐他汀 20 mg 联合低剂量地塞米松(或匹配安慰剂)每日一次,持续 28 天,随访 152 天。
  • 主要结局为 28 天时血肿体积较基线任何下降且无手术生存的复合良好结局。

核心结论

  • 该多中心临床试验旨在提供阿托伐他汀联合低剂量地塞米松通过减轻炎症和促进血管生成治疗慢性硬膜下血肿的有效性和安全性高质量证据。

研究设计与样本

  • ATOCH-II 为多中心、随机、安慰剂对照、双盲试验,计划纳入 240 例有保守治疗指征的成人慢性硬膜下血肿患者。
  • 患者随机分配至标准治疗联合阿托伐他汀 20 mg 加低剂量地塞米松(或匹配安慰剂)每日一次,持续 28 天,随访 152 天。

关键数值与推荐

  • 主要结局为 28 天时血肿体积较基线任何下降且无手术生存的复合良好结局。
  • 次要结局包括 28 天时改良 Rankin 量表(mRS)和改良 Barthel 指数的功能结局,以及 14、28、90 天时手术转换和血肿体积减少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic subdural haematoma (CSDH) is a common condition in the elderly that often requires neurosurgical management. For small CSDH, evidence has emerged that statins may reduce haematoma volume and improve outcomes, presumably by reducing local inflammation and promoting vascular repair. We wish to extend this evidence in a study that aims to determine the efficacy and safety of atorvastatin combined with low-dose dexamethasone in patients with CSDH. METHODS: The second ATorvastatin On Chronic subdural Hematoma (ATOCH-II) study is a multi-centre, randomized, placebo-controlled, double-blind trial which aims to enrol 240 adult patients with a conservative therapeutic indication for CSDH, randomly allocated to standard treatment with atorvastatin 20 mg combined with low-dose dexamethasone (or matching placebos) daily for 28 days, and with 152 days of follow-up. The primary outcome is a composite good outcome defined by any reduction from baseline in haematoma volume and survival free of surgery at 28 days. Secondary outcomes include functional outcome on the modified Rankin scale (mRS) and modified Barthel Index at 28 days, surgical transition and reduction in haematoma volumes at 14, 28 and 90 days. DISCUSSION: This multi-centre clinical trial aims to provide high-quality evidence on the efficacy and safety of the combined treatment of atorvastatin and low-dose dexamethasone to reduce inflammation and enhance angiogenesis in CSDH. TRIAL REGISTRATION: ChiCTR, ChiCTR1900021659 . Registered on 3 March 2019, http://www.chictr.org.cn/showproj.aspx?proj=36157 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jiang RC, Wang D, Zhao SG, et al. Atorvastatin combined with dexamethasone in chronic subdural haematoma (ATOCH II): study protocol for a randomized controlled trial. Trials. 2021. PMID: 34895306. doi:10.1186/s13063-021-05871-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。